Pancreatic Cancer Research

ResearcherUniversity of North Carolina at Chapel HillActive in the last 2 years

Bjoern Papke

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8156-7508; OpenAlex author ID A5015413269. Sources: funder_awards.

Their work

Papers
9
Trials
0
Grants
1
Labs led
0
Collaborators
43
Papers, trials and grants by year

2016: 1 grant · 2017: none · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 9

  1. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Co-author DOI 10.1016/j.celrep.2026.117627↗
  2. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-0391↗
  3. Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors. Co-author DOI 10.1158/0008-5472.can-21-1443↗
  4. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Co-author DOI 10.1016/j.celrep.2021.109291↗
  5. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Co-author DOI 10.1016/j.celrep.2021.110060↗
  6. The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer. Co-author DOI 10.1016/j.jbc.2021.101335↗
  7. Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Co-author DOI 10.1038/s41591-020-0947-8↗
  8. Atypical KRAS G12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-19-1006↗
  9. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Co-author DOI 10.1038/s41591-019-0368-8↗

Grants 1

  1. Visualization of KRas Perturbations in 3-dimensional Pancreatic Organoids AWARD pancan:2016-bjoern-papke-phd-visualization-of-kras-perturbations-in-3

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Adrienne D. Cox · 9 shared papers, 2019–2026 · strength 0.95
  2. Channing J. Der · 9 shared papers, 2019–2026 · strength 0.95
  3. Jennifer E. Klomp · 8 shared papers, 2019–2026 · strength 0.82
  4. Clint A. Stalnecker · 7 shared papers, 2019–2026 · strength 0.77
  5. Andrew M. Waters · 7 shared papers, 2019–2026 · strength 0.72
  6. Craig M. Goodwin · 6 shared papers, 2020–2026 · strength 0.71
  7. J. Nathaniel Diehl · 7 shared papers, 2019–2026 · strength 0.69
  8. Mariaelena Pierobon · 7 shared papers, 2019–2023 · strength 0.67
  9. Kirsten L. Bryant · 6 shared papers, 2019–2023 · strength 0.57
  10. Emanuel F. Petricoin · 6 shared papers, 2019–2022 · strength 0.54
  11. G. Aaron Hobbs · 5 shared papers, 2019–2026 · strength 0.49
  12. Tikvah K. Hayes · 4 shared papers, 2019–2026 · strength 0.41
  13. A. Cole Edwards · 3 shared papers, 2021–2026 · strength 0.40
  14. Devon R. Blake · 3 shared papers, 2021–2026 · strength 0.38
  15. Priya S. Hibshman · 3 shared papers, 2021–2026 · strength 0.38
  16. Lee M. Graves · 3 shared papers, 2021–2026 · strength 0.38
  17. Andrew J. Aguirre · 3 shared papers, 2020–2026 · strength 0.35
  18. Jonathan M. DeLiberty · 3 shared papers, 2020–2022 · strength 0.30
  19. William C. Hahn · 2 shared papers, 2021–2026 · strength 0.28
  20. Kristina Drizyte‐Miller · 2 shared papers, 2021–2023 · strength 0.23
  21. Nina V. Chaika · 2 shared papers, 2019–2020 · strength 0.14
  22. Yan Liang · 2 shared papers, 2019–2020 · strength 0.14
  23. Venugopal Gunda · 2 shared papers, 2019–2020 · strength 0.14
  24. Daniel Zeitouni · 2 shared papers, 2019–2020 · strength 0.14
  25. Yingxue Wang · 2 shared papers, 2019–2020 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.